Akero Therapeutics, Inc.

Ticker AKRO

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

11-50 Employees
Based in South San Francisco, California

Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, efruxifermin, has been evaluated in a 16-week Phase 2a clinical trial, the BALANCED study. Akero Therapeutics is headquartered in South San…More

Visit website

REPORT RATINGS

4.8 / 5.0 (198)

Akero Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 198 reviews.

Akero Therapeutics, Inc.